<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite the absence of a robust evidence base, there is growing consensus that effective treatment of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> leads to decreased morbidity and premature mortality in patients with good prognosis <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) </plain></SENT>
<SENT sid="1" pm="."><plain>Furthermore, new treatment modalities, including disease-modifying therapies (lenalidamide and azacytidine) and reduced intensity conditioning therapies for allogeneic blood stem cell transplants, are offering the prospect of longer survival for patients with traditionally less favourable prognosis <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, who might also benefit from iron chelation </plain></SENT>
<SENT sid="2" pm="."><plain>This article proposes assessment of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and related <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> syndromes to determine suitability for iron chelation </plain></SENT>
<SENT sid="3" pm="."><plain>Iron chelation therapy options and monitoring are discussed </plain></SENT>
</text></document>